Q2 EPS Estimates for Cytokinetics Reduced by HC Wainwright

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Equities researchers at HC Wainwright lowered their Q2 2025 EPS estimates for Cytokinetics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of ($1.47) for the quarter, down from their previous estimate of ($1.44). HC Wainwright currently has a "Buy" rating and a $120.00 target price on the stock. The consensus estimate for Cytokinetics' current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics' Q3 2025 earnings at ($1.45) EPS, Q4 2025 earnings at ($1.52) EPS and FY2025 earnings at ($5.80) EPS.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, beating the consensus estimate of ($1.41) by $0.05. The company had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.77 million. Cytokinetics's revenue was up 89.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.33) earnings per share.

CYTK has been the subject of several other reports. UBS Group dropped their target price on shares of Cytokinetics from $47.00 to $41.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Citigroup reduced their target price on Cytokinetics from $86.00 to $80.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Evercore ISI raised Cytokinetics to a "strong-buy" rating in a report on Friday, February 7th. Stifel Nicolaus assumed coverage on Cytokinetics in a research report on Wednesday, January 22nd. They set a "buy" rating and a $80.00 price objective for the company. Finally, Morgan Stanley set a $67.00 target price on Cytokinetics in a research note on Friday, March 7th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $74.44.

Cytokinetics Price Performance

Shares of NASDAQ CYTK traded down $0.61 during mid-day trading on Friday, reaching $30.00. The company had a trading volume of 2,019,835 shares, compared to its average volume of 1,672,314. Cytokinetics has a one year low of $29.95 and a one year high of $61.40. The business's 50-day simple moving average is $39.69 and its 200 day simple moving average is $45.68. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of -5.58 and a beta of 0.81.

Insiders Place Their Bets

In related news, EVP Andrew Callos sold 2,886 shares of Cytokinetics stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $35.78, for a total value of $103,261.08. Following the transaction, the executive vice president now directly owns 64,689 shares of the company's stock, valued at $2,314,572.42. The trade was a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $36.77, for a total transaction of $183,850.00. Following the sale, the chief executive officer now directly owns 422,629 shares of the company's stock, valued at $15,540,068.33. This represents a 1.17% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 95,362 shares of company stock valued at $3,899,118. 2.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cytokinetics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Harbor Capital Advisors Inc. boosted its position in shares of Cytokinetics by 6.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 45,130 shares of the biopharmaceutical company's stock valued at $2,123,000 after purchasing an additional 2,604 shares in the last quarter. Mirador Capital Partners LP boosted its holdings in shares of Cytokinetics by 1.6% during the 4th quarter. Mirador Capital Partners LP now owns 65,636 shares of the biopharmaceutical company's stock worth $3,088,000 after buying an additional 1,010 shares in the last quarter. Inspire Investing LLC boosted its holdings in shares of Cytokinetics by 7.8% during the 4th quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company's stock worth $400,000 after buying an additional 616 shares in the last quarter. Blue Trust Inc. grew its position in shares of Cytokinetics by 85.8% during the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 842 shares during the period. Finally, Pacer Advisors Inc. increased its stake in shares of Cytokinetics by 2.9% in the 4th quarter. Pacer Advisors Inc. now owns 24,843 shares of the biopharmaceutical company's stock valued at $1,169,000 after acquiring an additional 690 shares in the last quarter.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.